Immunosuppression in Older Kidney Transplant Recipients
Journal of the American Society of Nephrology · 2025
DOI: 10.1681/asn.0000000924 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Society of Nephrology, 2025. Verfasst von Jan-Stephan F Sanders und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Kidney Transplantation, Immunosuppressive Agents, Immunosuppression Therapy, Graft Rejection. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw, Chiesi Farmaceutici, ZonMw, Chiesi Farmaceutici.
Abstract (Originalsprache)
Key Points Low-dose tacrolimus, everolimus, and prednisolone did not result in a higher rate of successful transplantation in older kidney transplant recipients. Low-dose tacrolimus, everolimus, and prednisolone did not result in better kidney function or fewer infections in older kidney transplant recipients.
Background
We hypothesized that older kidney transplant recipients receiving low-dose tacrolimus, everolimus, and prednisolone (TEP) have better outcomes than patients receiving standard-dose tacrolimus, mycophenolate mofetil, and prednisolone (TMP).
Methods
The OPTIMIZE study was a randomized clinical trial in kidney transplant recipients age ≥65 years. Patients receiving a kidney from a deceased donor older than 65 years (stratum A) or a kidney from a deceased donor younger than 65 years or a living donor (stratum B) were included. Patients were randomized to TEP or TMP groups. Tacrolimus target trough levels in the TEP group were 5–7 ng/ml until 3 months, 2–4 ng/ml from 3 to 6 months, and 1.5–4 ng/ml from 6 months onwards. Tacrolimus target trough levels in the TMP group were 8–12, 6–10, and 5–8 ng/ml. Everolimus target trough levels were 3–6 µ g/L. The primary end point of successful transplantation was defined as being alive with a functioning graft with an eGFR above a predefined threshold at 2 years after transplantation. Predefined eGFR thresholds were 30 (stratum A) or 45 ml/min per 1.73 m 2 (stratum B).
Results
A total of 379 patients were randomized, of whom 198 were in stratum A (TEP 97, TMP 101) and 181 in stratum B (TEP 90, TMP 91). The median trough levels for everolimus and tacrolimus were within the target range throughout the study. There was no statistically significant difference in successful transplantation at 2 years between the groups (TEP 94 [50%], TMP 110 [57%]; difference 7% [95% confidence interval, −17 to 3] P = 0.91). Regarding the predefined secondary outcomes, patient survival (TEP 167 [89%], TMP 171 [89%]; P = 0.95) and graft survival (TEP 155 [83%], TMP 162 [84%]; P = 0.65) did not differ significantly. Within strata A and B, there were no significant differences in the end points.
Conclusions
Immunosuppression with low-dose tacrolimus, everolimus, and prednisolone did not result in a higher rate of successful transplantation in de novo older kidney transplant recipients compared with immunosuppression with standard-dose TMP. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT03797196.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- Renal Transplant Unit, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
- Division of Nephrology and Transplantation, Department of Internal Medicine, Erasmus MC Transplant Institute, Erasmus MC, Rotterdam, The Netherlands.
- Division of Nephrology, Department of Internal Medicine, Leiden Transplant Center, Leiden University Medical Center, Leiden University, Leiden, The Netherlands.
- Department of Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium.
ORCID-Profile: Jan-Stephan F Sanders, Silke E de Boer, Jip Jonker, Frederike J Bemelman, Michiel G H Betjes, Aiko P J de Vries, Luuk Hilbrands, Marc Hilhorst, Dirk R J Kuypers, Arjan D van Zuilen, Dennis A Hesselink, Stefan P Berger
Förderung
- ZonMw, Chiesi Farmaceutici
- ZonMw
- Chiesi Farmaceutici
Zitieren
APA
Sanders, J. F., de Boer, S. E., Jonker, J., Bemelman, F. J., Betjes, M. G. H., de Vries, A. P. J., Hilbrands, L., Hilhorst, M., Kuypers, D. R. J., Vart, P., van Zuilen, A. D., Hesselink, D. A., & Berger, S. P. (2025). Immunosuppression in Older Kidney Transplant Recipients. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.0000000924
Vancouver
Sanders JF, de Boer SE, Jonker J, Bemelman FJ, Betjes MGH, de Vries APJ, et al. Immunosuppression in Older Kidney Transplant Recipients. Journal of the American Society of Nephrology. 2025. doi:10.1681/asn.0000000924
BibTeX
@article{Sanders2025,
author = {Sanders, Jan-Stephan F and de Boer, Silke E and Jonker, Jip and Bemelman, Frederike J and Betjes, Michiel G H and de Vries, Aiko P J and Hilbrands, Luuk and Hilhorst, Marc and Kuypers, Dirk R J and Vart, Priya and van Zuilen, Arjan D and Hesselink, Dennis A and Berger, Stefan P},
title = {Immunosuppression in Older Kidney Transplant Recipients},
journal = {Journal of the American Society of Nephrology},
year = {2025},
doi = {10.1681/asn.0000000924}
}
EUVIMED